123 related articles for article (PubMed ID: 25721008)
21. Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
Cordeiro de Lima VC; Baldotto CS; Barrios CH; Sobrinho EM; Zukin M; Mathias C; Zaffaroni F; Nery RC; Madeira G; Amadio AV; Coelho JC; Geib G; Simões MF; Castro G
J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241276
[TBL] [Abstract][Full Text] [Related]
22. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
23. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
24. A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Sculier JP; Lafitte JJ; Berghmans T; Meert AP; Scherpereel A; Roelandts M; Van Cutsem O; Colinet B; Bonduelle Y; Giner V; Paesmans M; Leclercq N; Van Houtte P
Lung Cancer; 2018 Mar; 117():32-37. PubMed ID: 29496253
[TBL] [Abstract][Full Text] [Related]
25. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Gandara DR; Chansky K; Albain KS; Leigh BR; Gaspar LE; Lara PN; Burris H; Gumerlock P; Kuebler JP; Bearden JD; Crowley J; Livingston R;
J Clin Oncol; 2003 May; 21(10):2004-10. PubMed ID: 12743155
[TBL] [Abstract][Full Text] [Related]
26. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
27. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis.
Wang X; Ding X; Kong D; Zhang L; Guo Y; Ren J; Hu X; Yang J; Gao S
Int J Clin Oncol; 2017 Apr; 22(2):229-236. PubMed ID: 28005209
[TBL] [Abstract][Full Text] [Related]
28. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of Mean Platelet Volume on Local Advanced Non-Small Cell Lung Cancer Managed with Chemoradiotherapy.
Sakin A; Secmeler S; Arici S; Geredeli C; Yasar N; Demir C; Aksaray F; Cihan S
Sci Rep; 2019 Mar; 9(1):3959. PubMed ID: 30850724
[TBL] [Abstract][Full Text] [Related]
30. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
Hughes BG; Ahern E; Lehman M; Pratt G; Dauth M; Pritchard W; Wockner L; Horwood K
Asia Pac J Clin Oncol; 2017 Jun; 13(3):137-144. PubMed ID: 28181415
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.
Nakamichi S; Horinouchi H; Asao T; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Ito Y; Watanabe SI; Ohe Y
Clin Lung Cancer; 2017 Nov; 18(6):e441-e448. PubMed ID: 28583380
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer.
Sher DJ; Fidler MJ; Liptay MJ; Koshy M
Lung Cancer; 2015 Jun; 88(3):267-74. PubMed ID: 25862147
[TBL] [Abstract][Full Text] [Related]
34. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839.
Edelman MJ; Hu C; Le QT; Donington JS; D'Souza WD; Dicker AP; Loo BW; Gore EM; Videtic GMM; Evans NR; Leach JW; Diehn M; Feigenberg SJ; Chen Y; Paulus R; Bradley JD
J Thorac Oncol; 2017 Sep; 12(9):1413-1420. PubMed ID: 28629896
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Bastos BR; Hatoum GF; Walker GR; Tolba K; Takita C; Gomez J; Santos ES; Lopes G; Raez LE
J Thorac Oncol; 2010 Apr; 5(4):533-9. PubMed ID: 20357618
[TBL] [Abstract][Full Text] [Related]
37. With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Chen Y; Guo L; Cheng X; Wang J; Zhang Y; Wang Y; Ke S; Shi W
Radiother Oncol; 2018 Oct; 129(1):154-160. PubMed ID: 29122362
[TBL] [Abstract][Full Text] [Related]
38. The optimal chemotherapy timing in patients with inoperable locally advanced non small cell lung cancer.
Mutlu H; Büyükçelik A; Aslan T; Erden A; Akca Z
Med Arch; 2013; 67(2):104-6. PubMed ID: 24341055
[TBL] [Abstract][Full Text] [Related]
39. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
[TBL] [Abstract][Full Text] [Related]
40. Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives.
Antoni D; Mornex F
Curr Opin Oncol; 2016 Mar; 28(2):104-9. PubMed ID: 26848885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
